XML 97 R25.htm IDEA: XBRL DOCUMENT v3.22.4
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)
 12 Months Ended
Dec. 31, 2022
Novartis Institutes for BioMedical Research, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202220212020
Revenue related to Novartis agreement:
Recognition of upfront license fee$31,344 $29,945 $4,143 
Research services8,384 7,999 1,109 
Total$39,728 $37,944 $5,252 
Biogen MA, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202220212020
Revenue related to Biogen agreement:
Recognition of license and other fixed consideration$21,820 $29,224 $21,356 
Cost-sharing payments for research services, net variable consideration6,599 13,076 6,545 
Total$28,419 $42,300 $27,901 
Kite Pharma, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202220212020
Revenue related to Kite agreement:
Recognition of license fee fixed consideration$37,032 $24,977 $25,046 
Research services variable consideration1,560 476 3,562 
Total$38,592 $25,453 $28,608 
Pfizer, Giroctocogene Fitelparvovec  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202220212020
Revenue related to Pfizer giroctocogene fitelparvovec agreement:
Recognition of upfront fee and research services$— $— $3,111 
Milestone achievement— — 31,338 
Total$— $— $34,449 
Pfizer C9ORF72  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202220212020
Revenue related to Pfizer C9ORF72 agreement:
Recognition of upfront fee$— $— $7,985 
Milestone achievement— — 5,000 
Total$— $— $12,985 
Sanofi S.A.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202220212020
Revenue related to Sanofi agreement:
Recognition of upfront fee$677 $34 $298 
Research services2,126 3,057 4,823 
Milestone achievement457 23 201 
Total$3,260 $3,114 $5,322